OTCM
SCNLF
Market cap125mUSD
Nov 17, Last price
1.06USD
1Q
684.02%
IPO
103.85%
Name
Scancell Holdings PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Key people
Jean-Michel Cossery
Non-Executive Chairman of the Board · since 2023
Lindy Durrant
Chief Scientific Officer, Executive Director · since 2024
Phil L'Huillier
Chief Executive Officer, Executive Director · since 2024
Sathijeevan Nirmalananthan
Chief Financial Officer, Executive Director, Company Secretary · since 2024
Callum Scott
Head of Development · since 2024
Nermeen Varawalla
Chief Medical Officer · since 2024
Martin Diggle
Non-Executive Director · since 2019
Florian Reinaud
Non-Executive Director · since 2024
Susan Davies
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2019
Headquarters & legal address
BELLHOUSE BUILDING
SANDERS ROAD
OXFORD SCIENCE PARK
OXFORD, OXF OX4 4GD
GB
SANDERS ROAD
OXFORD SCIENCE PARK
OXFORD, OXF OX4 4GD
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑04 | 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||